Akamis Bio Secures $60M in Series A Prime Funding to Advance Oncology Pipeline

Cambridge, MA and Oxford, England, December 17, 2024 (Business Wire) -- Akamis Bio secured $60 million in Series A Prime funding and forged a licensing agreement with Xuanzhu Biopharma to advance its lead oncology candidate, NG-350A. The funding supports a Phase 1b proof-of-concept study evaluating NG-350A in combination with CRT for rectal cancer patients. The strategic partnership positions Akamis to expand globally while continuing to innovate in tumor-specific gene therapy.

Read full article here.